TAE226(NVP-TAE226)

Modify Date: 2024-01-02 18:27:42

TAE226(NVP-TAE226) structure	Common Name	TAE226(NVP-TAE226)
	CAS Number	761437-28-9	Molecular Weight	468.936
	Density	1.3±0.1 g/cm3	Boiling Point	N/A
	Molecular Formula	C₂₃H₂₅ClN₆O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of TAE226(NVP-TAE226)

NVP-TAE 226 is a dual tyrosine kinase inhibitor of FAK (IC50=5.5 nM) and IGF-IR (mean IC50=0.14 μM).

Name	2-((5-Chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide
Synonym	More Synonyms

Description	NVP-TAE 226 is a dual tyrosine kinase inhibitor of FAK (IC50=5.5 nM) and IGF-IR (mean IC50=0.14 μM).
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FAK Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Pyk2 Research Areas >> Cancer
Target	IC50: 5.5 nM (FAK), 3.5 nM (Pyk2), 0.14 μM (IGF-IR), 0.16 μM (c-Met), 0.36 μM (KDR), 0.48 μM (Flt3)[1]
In Vitro	NVP-TAE 226 (TAE226), a potent ATP-competitive inhibitor of several tyrosine protein kinases, in particular FAK and IGF-IR kinases. In a cell-based kinase assays, FAK, IGF-IR kinase, and IR kinase are inhibited with an IC50 range of 100 to 300 nM compared with the other kinases tested, which are >10-fold less sensitive. In culture, NVP-TAE 226 inhibits extracellular matrix-induced autophosphorylation of FAK (Tyr395). NVP-TAE 226 also inhibits IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt. NVP-TAE 226 retards tumor cell growth as assessed by a cell viability assay and attenuates G2-M cell cycle progression associated with a decrease in cyclin B1 and phosphorylated cdc2 (Tyr15) protein expression. NVP-TAE 226 treatment inhibits tumor cell invasion by at least 50% compared with the control in an in vitro Matrigel invasion assay. Interestingly, TAE226 treatment of tumor cells containing wild-type p53 mainly exhibits G2-M arrest, whereas tumor cells bearing mutant p53 underwent apoptosis[1].
In Vivo	Treatment with NVP-TAE 226 (TAE226) at 50 or 75 mg/kg extends the median survival of U87 xenograft animals by 6 and 7 days, respectively (P=0.084 and P=0.042, respectively, compared with vehicle-treated animals). However, NVP-TAE 226 treatment of LN229-engrafted animals significantly prolongs their median survival by 19 days (P<0.004 for both dosages, compared with vehicle-treated animals)[1].
Cell Assay	Glioma cell cultures are harvested with 0.05% trypsin and seeded in triplicate at 2×104 in 24-well culture plates for 24 h before drug treatment. Culture medium is used for mock treatment. Cells are harvested at the indicated day after treatment, and viable cells are counted using the Vi-cell viability analyzer. The antiproliferative activity of NVP-TAE 226 (ranging from 0.25 to 1 μM) on cells growing in culture is determined using a tetrazolium-based colorimetric MTT assay[1].
Animal Admin	Mice[1] Male nude mice used for this study are 6 to 8 weeks old. In DMEM/F12 serum-free media (5 μL), 5×105 of U87 cells and 1×106 of LN229 cells per mouse are implanted intracranially through a guide-screw system. Four days after injection of the tumor cells, mice are randomized into three groups for each cell line (n=6). Mice in group 1 are treated with 50 mg/kg NVP-TAE 226 in 200 μL of 0.5% methylcellulose, via an oral gavage. The mice in group 2 receive 75 mg/kg NVP-TAE 226 in 200 μL of 0.5% methylcellulose. The mice in group 3 the same vehicle used for administration of NVP-TAE 226 (control). Treatment frequency is once a day for 5 days and off for 2 days, for a duration of 4 weeks. Mice are monitored daily. Mice are euthanized when they are moribund, and the whole brain is extracted for rapid freezing in liquid nitrogen and storage at -70°C.
References	[1]. Liu TJ, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther, 2007, 6(4), 1357-1367. [2]. Delimont D, et al. Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS One. 2014 Jun 10;9(6):e99083.

Density	1.3±0.1 g/cm3
Molecular Formula	C₂₃H₂₅ClN₆O₃
Molecular Weight	468.936
Exact Mass	468.167664
PSA	100.64000
LogP	2.35
Appearance of Characters	light yellow solid
Index of Refraction	1.659
Storage condition	-20℃

HS Code	2934999090

HS Code	2934999090
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-N-methylbenzamide

2-[(5-Chloro-2-{[2-methoxy-4-(4-morpholinyl)phenyl]amino}-4-pyrimidinyl)amino]-N-methylbenzamide

Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-

NVP-TAE 226

TAE226

DC Chemicals Limited
China
Product Name: NVP-TAE226
Price: $600.0/100mg $1000.0/250mg $1900.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: 2-((5-CHLORO-2-((2-METHOXY-4-MORPHOLINOPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-N-METHYLBENZAMIDE
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

Get all suppliers and price by the below link:

TAE226(NVP-TAE226) suppliers

Price: $160/10mM*1mLinDMSO

Reference only. check more TAE226(NVP-TAE226) price

TAE226(NVP-TAE226)

Use of TAE226(NVP-TAE226)

Names

TAE226(NVP-TAE226) Biological Activity

Chemical & Physical Properties

Safety Information

Customs

Synonyms